PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
Background. Belimumab (BEL) and Anifrolumab (ANI) are currently the only biologic drugs authorized for the treatment of Systemic Lupus Erythematosus (SLE). The aim of the study is to analyze the factors associated with the therapeutic choice between BEL and ANI in a monocentric cohort of patients a...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
PAGEPress Publications
2025-11-01
|
| Serie: | Reumatismo |
| Soggetti: | |
| Accesso online: | https://www.reumatismo.org/reuma/article/view/2167 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|